Autopsy report · NCT02127151

A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer

“Withdrawal of Industry support for the study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

University College, London

Sponsor type

University, hospital or other

Conditions

Endometrial Cancer

Interventions

BMN 673

Participants

0

Sites

16

Countries

United Kingdom

Trials that died the same way

• Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery
  “This study was withdrawn for business reasons.” (77% match in meaning)
• A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
  “Study was withdrawn due to scientific and business considerations.” (76% match in meaning)
• Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients
  “The study withdrawn due to lack financial support” (73% match in meaning)
• Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
  “Study is withdrawn due to company decision.” (73% match in meaning)
• Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study
  “Study was withdrawn for feasibility-related concerns.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.